EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial

Somnath Mukherjee, Cathy Qi, Rachel Shaw, Christopher M Jones, John A Bridgewater, Ganesh Radhakrishna, Neel Patel, Jane Holmes, Pradeep S Virdee, Bethan Tranter, Philip Parsons, Stephen Falk und 11 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114236 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Somnath Mukherjee und 22 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: somnath.mukherjee@ouh.nhs.uk. Hauptthemen laut MEDLINE: Nelfinavir, Pancreatic Neoplasms, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NelfinavirPancreatic NeoplasmsChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultPaclitaxelMaximum Tolerated DoseDeoxycytidineGemcitabineAged, 80 and overQuality of LifeAlbuminsProgression-Free SurvivalProtease Inhibitors

Stichwörter der Autor:innen

ChemoradiotherapyDose escalationHealth-related quality of lifeNelfinavirOutcomesPancreatic cancerSurvivalToxicity

Substanzen

NelfinavirPaclitaxel130-nm albumin-bound paclitaxelDeoxycytidineGemcitabineAlbuminsProtease Inhibitors

Autor:innen und Institutionen

  • Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: somnath.mukherjee@ouh.nhs.uk.
  • Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
  • Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, UK.
  • Department of Oncology, University of Cambridge, Cambridge, UK; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • UCL Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK.
  • The Christie Hospital, The Christie Hospitals NHS Foundation Trust, Manchester, UK.

Förderung

  • Cancer Research UK

Zitieren

APA

Mukherjee, S., Qi, C., Shaw, R., Jones, C. M., Bridgewater, J. A., Radhakrishna, G., Patel, N., Holmes, J., Virdee, P. S., Tranter, B., Parsons, P., Falk, S., Wasan, H. S., Ajithkumar, T. V., Holyoake, D., Roy, R., Scott-Brown, M., Hurt, C. N., O'Neill, E., …, & Corrie, P. (2024). Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114236

Vancouver

Mukherjee S, Qi C, Shaw R, Jones CM, Bridgewater JA, Radhakrishna G, et al. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114236

BibTeX
@article{Mukherjee2024,
  author = {Mukherjee, Somnath and Qi, Cathy and Shaw, Rachel and Jones, Christopher M and Bridgewater, John A and Radhakrishna, Ganesh and Patel, Neel and Holmes, Jane and Virdee, Pradeep S and Tranter, Bethan and Parsons, Philip and Falk, Stephen and Wasan, Harpreet S and Ajithkumar, Thankamma V and Holyoake, Daniel and Roy, Rajarshi and Scott-Brown, Martin and Hurt, Christopher N and O'Neill, Eric and Sebag-Montefiore, David and Maughan, Tim S and Hawkins, Maria A and Corrie, Pippa},
  title = {Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114236}
}
Kostenlos starten →